
Strides Pharma Science Limited has informed the Exchange regarding a press release dated December 28, 2022, titled "Stelis Biopharma s CDMO partner receives approval for a key ANDA from the USFDA".
Filed with NSE ·

Strides Pharma Science Limited has informed the Exchange regarding a press release dated December 28, 2022, titled "Stelis Biopharma s CDMO partner receives approval for a key ANDA from the USFDA".
6ix hasn’t read this filing yet.
Strides Pharma Science Ltd on 6ix
Follow Strides Pharma Science into a list and get an email when it puts out news.
Follow Strides Pharma Science